Further Anomeric Esters
3.3
537
⊡ Scheme 26
(Ref. [34])
⊡ Scheme 27
(Ref. [35])
⊡ Scheme 28
(Ref. [36])
nosyl acetate donors by a similar methodology ( > Scheme 28) [36]. Kaneko et al. reported
an approach to the stereoselective semi-synthesis of GM-237354, a potent inhibitor of fungal
elongation factor 2 (EF-2), by employing a highly β-selective glycosylation using 2-deoxy2-iodo-glycopyranosyl acetate donor developed by the Roush group ( > Scheme 29) [37].
Roush et al. also reported the use of TBSOTf as an activator for the glycosylation reactions
with L-rhodinosyl (2,3,6-trideoxy-L-hexosyl) acetate derivatives in synthesizing the repeat
A-B-C trisaccharide unit of Landomycin A ( > Scheme 30) [38], and for the glycosylation reaction with α-L-rhamnopyranosyl acetate in the early stage of the synthesis of (–)-spinosyn A
( > Scheme 31) [39].
3.3
537
⊡ Scheme 26
(Ref. [34])
⊡ Scheme 27
(Ref. [35])
⊡ Scheme 28
(Ref. [36])
nosyl acetate donors by a similar methodology ( > Scheme 28) [36]. Kaneko et al. reported
an approach to the stereoselective semi-synthesis of GM-237354, a potent inhibitor of fungal
elongation factor 2 (EF-2), by employing a highly β-selective glycosylation using 2-deoxy2-iodo-glycopyranosyl acetate donor developed by the Roush group ( > Scheme 29) [37].
Roush et al. also reported the use of TBSOTf as an activator for the glycosylation reactions
with L-rhodinosyl (2,3,6-trideoxy-L-hexosyl) acetate derivatives in synthesizing the repeat
A-B-C trisaccharide unit of Landomycin A ( > Scheme 30) [38], and for the glycosylation reaction with α-L-rhamnopyranosyl acetate in the early stage of the synthesis of (–)-spinosyn A
( > Scheme 31) [39].